Research news · Moneycontrol.com

Novo's Manufacturing Pivot Reinforces Peptide CDMO Sector Case

Novo's Manufacturing Pivot Reinforces Peptide CDMO Sector Case

Moneycontrol.com reported in October 2026 that Novo Nordisk's manufacturing pivot has reinforced the investment case for peptide contract development and manufacturing organisations, with Divi's Laboratories named as Macquarie's top Indian pick in the sector.

Source: Novo's manufacturing pivot reinforces peptide CDMO case; Divi's is Macquarie's top Indian pick (Moneycontrol.com)

Related in the Skinni library

How Skinni approaches the science

For research use only. This brief summarises a third-party report; it is not a claim about any Skinni product and not medical advice.

More research news

All briefs
Peptide Quality Standards Shift as Development Advances

Research news · Manufacturing Chemist

Peptide Quality Standards Shift as Development Advances

Manufacturing Chemist reported in October 2026 that peptide quality requirements change as a compound moves from research grade through to GMP, with distinct standards applying at each stage of development.

October 22, 2026Read the brief
Potency data that cannot travel between labs

Research news · Big Easy Magazine

Potency data that cannot travel between labs

Big Easy Magazine reported in October 2026 that assay reproducibility for melanocortin peptides is under scrutiny, with potency data shown not to transfer reliably between laboratories.

October 21, 2026Read the brief
Peptide Edits Produce Unpredictable Anti-Inflammatory Results

Research news · Bioengineer.org

Peptide Edits Produce Unpredictable Anti-Inflammatory Results

Bioengineer.org reported in October 2026 that FELL peptide edits reveal unpredictable anti-inflammatory activity, according to new research findings.

October 20, 2026Read the brief